An interventional study of Pregabalin and Lacosamide in Herpes Zoster (HZ) and Post Herpetic Neuralgia (PHN), sponsored by CMH Kharian Medical College. Recruiting at 1 site in Pakistan. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-05-14.
Sponsored by CMH Kharian Medical College · Not applicable, Interventional, and Treatment
Post-herpetic neuralgia (PHN) is the most significant complication of herpes zoster caused by reactivation of latent Varicella-Zoster virus (VZV). PHN is characterized by neuropathic pain lasting beyond the resolution of the rashes. Post herpetic neuralgia (PHN) represents a potentially debilitating and often undertreated form of neuropathic pain that disproportionately affects vulnerable populations, including the elderly and the immunocompromised. PHN pain is typically localized, unilateral and chronic, but may be constant, intermittent, spontaneous and/or evoked. PHN is likely to interfere with sleep and daily activities.
Pregabalin is a gabapentinoid licenced for treatment of neurological disorders. It is one of the earlier drugs approved by the US Food and Drug Administration (2004) for the treatment of painful diabetic neuropathy and postherpetic neuralgia (PHN). Lacosamide (LCM) was approved in 2008 in the European Union and in the United States as adjunctive therapy for the treatment of focal-onset seizures with or without secondary generalization in adults and adolescents with epilepsy. Its efficacy has also been proven in neuropathic pain.
Although Pregabalin and Lacosamide have proven effective in various neuropathic pain disorder, comparative studies specifically for PHN remain scarce. This study aims to compare the efficacy of Pregabalin and Lacosamide in PHN patients, addressing the current gap in literature and providing clinically relevant insights to optimize treatment selection.
370 studies on the registry are indexed under Herpes Zoster; 63 are open to participants now.
This study's planned enrollment of 50 is below the median of 242 across 306 interventional studies indexed under Herpes Zoster.
Browse Herpes Zoster studies →CMH Kharian Medical College is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Group A will receive Cap Pregabalin, the first intervention
Drug: Pregabalin
Group B will receive Tab Lacosamide
Drug: Lacosamide
o Group A will receive Cap Pregabalin 150mg oral OD for 4 weeks
o Group B will receive Tab Lacosamide 100mg oral BD for 4 weeks
Visual Analog Scale
Pain intensity will be measured before and after treatment with help of Visual Analog Scale.
Time frame: 4 weeks
Plan to share: Undecided — The decision will be taken after getting consent from each participant.
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Jul 2025, 3 months after the start.
Of 33 interventional studies with no phase under Herpes Zoster, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's planned 3 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lacosamide
CMH Kharian Medical College